-
Mashup Score: 0Don’t Shy Away From Discussing MPN Side Effects - 10 month(s) ago
Patients being treated for a myeloproliferative neoplasm should be open with their care team about any side effects they experience, an expert said.
Source: Cure TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Hope Is Paramount During Uveal Melanoma Treatment - 10 month(s) ago
An expert gives an overview of the treatment options for uveal melanoma, and why he considers hope to be an essential part of the care plan.
Source: Cure TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
R. Christopher Bowen, MD, (@EyecancerMD) of @LurieCancer @NorthwesternMed discusses #uvealmelanoma treatment options and support to help patients live as long and as well as possible with this rare diagnosis. https://t.co/G0FqiMyndT via @curetoday #ocularmelanoma
-
-
Mashup Score: 0Lining Up New Options for GIST - 10 month(s) ago
Patients with GIST have more treatment options than ever, with others currently under development.
Source: Cure TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Margaret von Mehren, chief of sarcoma medical oncology at Fox Chase Cancer Center, provided expert commentary to a @cure_today article on the lineup of new options for GIST. Read it here ⬇️ https://t.co/mWXBZm2nwe
-
-
Mashup Score: 1‘There’s a Lot of Innovation’ in the KRAS-Mutant Lung Cancer Space - 11 month(s) ago
An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.
Source: Cure TodayCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to collaborate w @GO2forLungCancr on the SPARK trial to better understand the complexities of KRAS inhibitor resistance! https://t.co/q2VeleciXU
-
-
Mashup Score: 3Non-English- Speaking Patients With Cancer Face Big Barriers to Care in the U.S., But Help Is Available - 11 month(s) ago
For patients who don’t speak English, there can be additional obstacles during their cancer journey. Resources, family, care providers, fellow patients and the law are on their side.
Source: Cure TodayCategories: Hem/Oncs, Latest HeadlinesTweet-
‼️Know your rights: Access to medical interpreters is not just a #healthequity but a #compliance issue‼️ Non-English- Speaking Patients With Cancer Face Big Barriers to Care in the U.S., But Help Is Available https://t.co/PaGqAnyeN2 via @curetoday #patienteducation… https://t.co/9aQtG1TMJp
-
-
Mashup Score: 0Making Magic Happen in Cancer Care - 11 month(s) ago
During an uncertain time, Missy Bean-Tanner, RN, brings inner peace and reassurance. She will jump into anything if she knows it will help her patients.
Source: Cure TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"Prior to my initial chemotherapy session, Missy (Bean-Tanner, RN) learned that I was going to arrive dressed up as Wonder Woman. My first introduction was seeing her dressed as Wonder Woman as a show of support," wrote Pamela Fields. @TulaneMedicine https://t.co/4qRjvTupoW
-
-
Mashup Score: 0Educated Patient® Multiple Myeloma Summit the Role of BMT Presentation: April 8, 2023 - 12 month(s) ago
Watch Dr. Marc Braunstein, from NYU Langone Hospital, discuss the role of bone marrow transplant during the CURE Educated Patient Multiple Myeloma Summit.
Source: Cure TodayCategories: Hem/Oncs, Latest HeadlinesTweet-
Overview of stem cell transplantation for #myeloma hosted by @cure_today at the April 2023 Educated Patient® Multiple Myeloma Summit. #mmsm. @Perlmutter_CC https://t.co/10G1WlhtbV
-
-
Mashup Score: 6New Myeloma Therapies Are ‘A Huge Improvement for the Field’ - 12 month(s) ago
Triplet therapy demonstrates improved remission and survival rates, with manageable side effects for patients who are ineligible for transplant.
Source: Cure TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“We want patients not only to live longer but also be able to enjoy that time," says our Dr. Robert Orlowski of a recent study he led examining triplet therapy for myeloma treatment. Learn more about his research here: https://t.co/WEOYSz65g5 @Myeloma_Doc #EndCancer
-
-
Mashup Score: 2There’s ‘Unmistakable Momentum’ in MPN Advances, Expert Says - 1 year(s) ago
Dr. Naveen Pemmaraju outlines three reasons why he feels that there is “a momentum that’s unmistakable,” in the field of myeloproliferative neoplasms.
Source: Cure TodayCategories: Hem/Oncs, Latest HeadlinesTweet-
🙌 A lot of exciting progress &momentum in our MPN research field, let’s keep it going through 🌎 collaborations together! @cure_today | @mpdrc @jjkiladjian @HarryGillHKUMed @harrisoncn1 @Mohty_EBMT @RaajitRampal @DeeptiRadia @AdamMead_Oxford https://t.co/7cLQTnKo5t | #MPNSM
-
-
Mashup Score: 1
Findings from a study demonstrated that patients may develop hypertension, or high blood pressure, as a result of treatment with Imbruvica for CLL, although it may be quickly managed without drug-drug interactions.
Source: Cure TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
High blood pressure is a common side effect of Imbruvica. Learn what our Dr. Alessandra Ferrajoli advises for patients being treated with Imbruvica for chronic lymphocytic leukemia. https://t.co/N15SmwMz53 @cure_today #Leukemia #EndCancer
-
Patients may feel hesitant to discuss side effects with their care team in fear of being taken off treatment. But they shouldn’t be, our Julie Huynh-Lu explains. https://t.co/8rK5hAWN0z @curetoday #EndCancer